# Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.

> **NCT03242382** · PHASE2 · UNKNOWN · sponsor: **Grupo Espanol de Investigacion en Sarcomas** · enrollment: 40 (estimated)

## Conditions studied

- Soft-tissue Sarcoma
- Osteosarcoma
- Chordoma

## Interventions

- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT03242382
- **Lead sponsor:** Grupo Espanol de Investigacion en Sarcomas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-31
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03242382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03242382, "Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03242382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*